These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
152 related items for PubMed ID: 15531509
1. Age and secretagogue type jointly determine dynamic growth hormone responses to exogenous insulin-like growth factor-negative feedback in healthy men. Veldhuis JD, Weltman JY, Weltman AL, Iranmanesh A, Muller EE, Bowers CY. J Clin Endocrinol Metab; 2004 Nov; 89(11):5542-8. PubMed ID: 15531509 [Abstract] [Full Text] [Related]
2. Contrasting negative-feedback control of endogenously driven and exercise-stimulated pulsatile growth hormone secretion in women and men. Veldhuis JD, Patrie J, Wideman L, Patterson M, Weltman JY, Weltman A. J Clin Endocrinol Metab; 2004 Feb; 89(2):840-6. PubMed ID: 14764803 [Abstract] [Full Text] [Related]
3. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans. Ghigo E, Gianotti L, Arvat E, Ramunni J, Valetto MR, Broglio F, Rolla M, Cavagnini F, Müller EE. J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097 [Abstract] [Full Text] [Related]
4. Accelerated escape from GH autonegative feedback in midpuberty in males: evidence for time-delimited GH-induced somatostatinergic outflow in adolescent boys. Richmond E, Rogol AD, Basdemir D, Veldhuis OL, Clarke W, Bowers CY, Veldhuis JD. J Clin Endocrinol Metab; 2002 Aug; 87(8):3837-44. PubMed ID: 12161519 [Abstract] [Full Text] [Related]
6. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans. Gianotti L, Maccario M, Lanfranco F, Ramunni J, Di Vito L, Grottoli S, Muller EE, Ghigo E, Arvat E. J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509 [Abstract] [Full Text] [Related]
7. Estradiol supplementation modulates growth hormone (GH) secretory-burst waveform and recombinant human insulin-like growth factor-I-enforced suppression of endogenously driven GH release in postmenopausal women. Veldhuis JD, Anderson SM, Kok P, Iranmanesh A, Frystyk J, Ørskov H, Keenan DM. J Clin Endocrinol Metab; 2004 Mar; 89(3):1312-8. PubMed ID: 15001627 [Abstract] [Full Text] [Related]
8. Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback. Chapman IM, Hartman ML, Pezzoli SS, Harrell FE, Hintz RL, Alberti KG, Thorner MO. J Clin Endocrinol Metab; 1997 Sep; 82(9):2996-3004. PubMed ID: 9284733 [Abstract] [Full Text] [Related]
9. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD. J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555 [Abstract] [Full Text] [Related]
10. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ. J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205 [Abstract] [Full Text] [Related]
11. Unequal impact of short-term testosterone repletion on the somatotropic axis of young and older men. Gentili A, Mulligan T, Godschalk M, Clore J, Patrie J, Iranmanesh A, Veldhuis JD. J Clin Endocrinol Metab; 2002 Feb; 87(2):825-34. PubMed ID: 11836328 [Abstract] [Full Text] [Related]
12. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states. Evans WS, Anderson SM, Hull LT, Azimi PP, Bowers CY, Veldhuis JD. J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034 [Abstract] [Full Text] [Related]
13. Estradiol supplementation enhances submaximal feed-forward drive of growth hormone (GH) secretion by recombinant human GH-releasing hormone-1,44-amide in a putatively somatostatin-withdrawn milieu. Veldhuis JD, Evans WS, Bowers CY. J Clin Endocrinol Metab; 2003 Nov; 88(11):5484-9. PubMed ID: 14602794 [Abstract] [Full Text] [Related]
14. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity. Maccario M, Tassone F, Gianotti L, Lanfranco F, Grottoli S, Arvat E, Muller EE, Ghigo E. J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996 [Abstract] [Full Text] [Related]
15. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256 [Abstract] [Full Text] [Related]
16. Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy. Veldhuis JD, Keenan DM, Mielke K, Miles JM, Bowers CY. Eur J Endocrinol; 2005 Oct; 153(4):577-86. PubMed ID: 16189179 [Abstract] [Full Text] [Related]
17. Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa. Gianotti L, Pincelli AI, Scacchi M, Rolla M, Bellitti D, Arvat E, Lanfranco F, Torsello A, Ghigo E, Cavagnini F, Müller EE. J Clin Endocrinol Metab; 2000 Aug; 85(8):2805-9. PubMed ID: 10946886 [Abstract] [Full Text] [Related]
18. Testosterone blunts feedback inhibition of growth hormone secretion by experimentally elevated insulin-like growth factor-I concentrations. Veldhuis JD, Anderson SM, Iranmanesh A, Bowers CY. J Clin Endocrinol Metab; 2005 Mar; 90(3):1613-7. PubMed ID: 15585557 [Abstract] [Full Text] [Related]
19. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Khorram O, Laughlin GA, Yen SS. J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536 [Abstract] [Full Text] [Related]
20. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men. Iranmanesh A, South S, Liem AY, Clemmons D, Thorner MO, Weltman A, Veldhuis JD. Eur J Endocrinol; 1998 Jul; 139(1):59-71. PubMed ID: 9703380 [Abstract] [Full Text] [Related] Page: [Next] [New Search]